Payment overview · 2025
General Payments
$885.39
32 reported records · 13 companies
Healthcare provider profile · identity verified
Ilya Kleyn, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1851327092
Verified facts
What the public records show
CMS Open Payments records show Ilya Kleyn, MD received $885.39 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Mounjaro, Ozempic, Rayaldee, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rayaldee by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $345.51 | 39.0% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $80.74 | 9.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $80.13 | 9.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.70 | 7.9% | 3 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $67.40 | 7.6% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $47.46 | 5.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.16 | 4.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $39.90 | 4.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.12 | 3.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $26.20 | 3.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.12 | 2.3% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.67 | 2.1% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $18.28 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $817.99 | 29 |
| Education | $67.40 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $149.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $105.51 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $105.51 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $80.74 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $80.13 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $70.89 | 3 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $67.40 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.89 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $47.46 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.12 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 159 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 128 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
159 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
128 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1175 | 250 |
| Amlodipine Besylate | Amlodipine Besylate | 873 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 796 | 159 |
| Losartan Potassium | Losartan Potassium | 643 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 642 | 136 |
| Lisinopril | Lisinopril | 469 | 91 |
| Eliquis | Apixaban | 425 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 89 |
| Donepezil Hcl | Donepezil Hcl | 378 | 73 |
| Simvastatin | Simvastatin | 375 | 69 |
| Omeprazole | Omeprazole | 354 | 88 |
| Furosemide | Furosemide | 341 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 335 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 326 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 320 | 84 |
| Diclofenac Sodium | Diclofenac Sodium | 314 | 80 |
| Metformin Hcl | Metformin Hcl | 304 | 80 |
| Mirtazapine | Mirtazapine | 288 | 56 |
| Memantine Hcl | Memantine Hcl | 259 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 259 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 230 | 60 |
| Famotidine | Famotidine | 226 | 55 |
| Gabapentin | Gabapentin | 222 | 63 |
| Hydralazine Hcl | Hydralazine Hcl | 216 | 48 |
| Carvedilol | Carvedilol | 214 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 45 |
| Finasteride | Finasteride | 198 | 31 |
| Sertraline Hcl | Sertraline Hcl | 178 | 38 |
| Montelukast Sodium | Montelukast Sodium | 164 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 161 | 34 |
| Creon | Lipase/Protease/Amylase | 159 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 142 | 27 |
| Potassium Chloride | Potassium Chloride | 141 | 39 |
| Nifedipine Er | Nifedipine | 137 | 28 |
| Linzess | Linaclotide | 128 | 27 |
| Xarelto | Rivaroxaban | 127 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 21 |
| Alendronate Sodium | Alendronate Sodium | 123 | 19 |
| Allopurinol | Allopurinol | 123 | 26 |
| Valsartan | Valsartan | 118 | 28 |
| Januvia | Sitagliptin Phosphate | 117 | 29 |
| Myrbetriq | Mirabegron | 114 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 113 | 38 |
| Torsemide | Torsemide | 103 | 19 |
| Trazodone Hcl | Trazodone Hcl | 103 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 18 |
| Spironolactone | Spironolactone | 96 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 82 | 14 |
| Folic Acid | Folic Acid | 79 | 16 |
| Ezetimibe | Ezetimibe | 78 | 15 |
| Atenolol | Atenolol | 76 | 18 |
| Metformin Hcl Er | Metformin Hcl | 72 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 16 |
| Levetiracetam | Levetiracetam | 67 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 32 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 66 | 28 |
| Jardiance | Empagliflozin | 65 | 18 |
| Meclizine Hcl | Meclizine Hcl | 65 | 21 |
| Clonidine Hcl | Clonidine Hcl | 62 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 13 |
| Latanoprost | Latanoprost | 62 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 13 |
| Bupropion Xl | Bupropion Hcl | 61 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 60 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 58 | 43 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 56 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 16 |
| Buspirone Hcl | Buspirone Hcl | 53 | 11 |
| Doxepin Hcl | Doxepin Hcl | 52 | 17 |
| Vascepa | Icosapent Ethyl | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Azithromycin | Azithromycin | 49 | 43 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | suppressed |
| Lidocaine | Lidocaine | 49 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 21 |
| Methimazole | Methimazole | 46 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 45 | 15 |
| Labetalol Hcl | Labetalol Hcl | 45 | suppressed |
| Repaglinide | Repaglinide | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 16 |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 38 |
| Glimepiride | Glimepiride | 42 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 14 |
| Glipizide Er | Glipizide | 40 | suppressed |
| Risperidone | Risperidone | 40 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 39 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 12 |
| Ramipril | Ramipril | 38 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | 11 |
| Baclofen | Baclofen | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 30 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | 18 |
| Sucralfate | Sucralfate | 34 | 11 |
| Ibuprofen | Ibuprofen | 33 | 16 |
| Mupirocin | Mupirocin | 33 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Prednisone | Prednisone | 32 | suppressed |
| Anastrozole | Anastrozole | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | 12 |
| Restasis | Cyclosporine | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 31 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 30 | suppressed |
| Calcitriol | Calcitriol | 30 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Clotrimazole | Clotrimazole | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Alphagan P | Brimonidine Tartrate | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Lumigan | Bimatoprost | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 18 |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Diovan | Valsartan | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Letrozole | Letrozole | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Victoza 2-Pak | Liraglutide | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Jublia | Efinaconazole | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Rayaldee | Calcifediol | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Inbrija | Levodopa | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $885.39 · 32 records | ABBVIE INC. | AIRSUPRA, APRETUDE, BREZTRI, CAPLYTA, CREON, ELYXYB - CELECOXIB, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, NEFFY, Ozempic, QULIPTA, RAYALDEE, REXULTI, Rybelsus, TEPEZZA, UBRELVY, VRAYLAR, ZEPBOUND, ZTLido | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error